Cargando…

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes

BACKGROUND: This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL/METHODS: A total of 48 patients with metastatic TNBC that fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junbin, Zheng, Rongsheng, Wang, Zishu, Yang, Yan, Wang, Mingxi, Zou, Weiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629993/
https://www.ncbi.nlm.nih.gov/pubmed/28957036
http://dx.doi.org/10.12659/MSM.905300
_version_ 1783269156827693056
author Wang, Junbin
Zheng, Rongsheng
Wang, Zishu
Yang, Yan
Wang, Mingxi
Zou, Weiyan
author_facet Wang, Junbin
Zheng, Rongsheng
Wang, Zishu
Yang, Yan
Wang, Mingxi
Zou, Weiyan
author_sort Wang, Junbin
collection PubMed
description BACKGROUND: This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL/METHODS: A total of 48 patients with metastatic TNBC that failed in anthracyclines and taxanes treatment were enrolled and randomly grouped. Patients in the NP group (n=22) were given 25 mg/m(2) vinorelbine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle, while subjects in the GP group (n=26) were administered 1000 mg/m(2) gemcitabine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle. The treatment response and adverse events were compared between the 2 groups every 2 cycles. RESULTS: The ORR, DCR, and median TTP were 45.5%, 77.3%, and 5 months in the NP group, and 46.2%, 80.8%, and 5.2 months in the GP group, and no significant differences were observed in ORR, DCR, and median TTP between the 2 groups (P>0.05). The major adverse events included grade I–II bone marrow inhibition, gastrointestinal reactions, and phlebitis, and a lower incidence of thrombocytopenia and rash and a higher incidence of phlebitis was found in the NP group than in the GP group (P<0.05). CONCLUSIONS: Either NP or GP regimen is active and tolerated in treatment of metastatic TNBC with anthracyclines and/or taxanes resistance, which may be used as a salvage treatment for metastatic TNBC.
format Online
Article
Text
id pubmed-5629993
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-56299932017-10-13 Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes Wang, Junbin Zheng, Rongsheng Wang, Zishu Yang, Yan Wang, Mingxi Zou, Weiyan Med Sci Monit Clinical Research BACKGROUND: This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL/METHODS: A total of 48 patients with metastatic TNBC that failed in anthracyclines and taxanes treatment were enrolled and randomly grouped. Patients in the NP group (n=22) were given 25 mg/m(2) vinorelbine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle, while subjects in the GP group (n=26) were administered 1000 mg/m(2) gemcitabine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle. The treatment response and adverse events were compared between the 2 groups every 2 cycles. RESULTS: The ORR, DCR, and median TTP were 45.5%, 77.3%, and 5 months in the NP group, and 46.2%, 80.8%, and 5.2 months in the GP group, and no significant differences were observed in ORR, DCR, and median TTP between the 2 groups (P>0.05). The major adverse events included grade I–II bone marrow inhibition, gastrointestinal reactions, and phlebitis, and a lower incidence of thrombocytopenia and rash and a higher incidence of phlebitis was found in the NP group than in the GP group (P<0.05). CONCLUSIONS: Either NP or GP regimen is active and tolerated in treatment of metastatic TNBC with anthracyclines and/or taxanes resistance, which may be used as a salvage treatment for metastatic TNBC. International Scientific Literature, Inc. 2017-09-28 /pmc/articles/PMC5629993/ /pubmed/28957036 http://dx.doi.org/10.12659/MSM.905300 Text en © Med Sci Monit, 2017 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Wang, Junbin
Zheng, Rongsheng
Wang, Zishu
Yang, Yan
Wang, Mingxi
Zou, Weiyan
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
title Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
title_full Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
title_fullStr Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
title_full_unstemmed Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
title_short Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
title_sort efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629993/
https://www.ncbi.nlm.nih.gov/pubmed/28957036
http://dx.doi.org/10.12659/MSM.905300
work_keys_str_mv AT wangjunbin efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes
AT zhengrongsheng efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes
AT wangzishu efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes
AT yangyan efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes
AT wangmingxi efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes
AT zouweiyan efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes